# Replicor Compassionate Access Program

> **NCT05683548** · — · NO_LONGER_AVAILABLE · sponsor: **Replicor Inc.**

## Conditions studied

- Viral Hepatitis B
- Viral Hepatitis D
- Cirrhosis, Liver
- Decompensated Cirrhosis
- Ascites Hepatic
- Varices, Esophageal
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** REP 2139-Mg
- **DRUG:** Tenofovir Disoproxil Fumarate
- **DRUG:** Pegylated interferon alpha2a

## Key facts

- **NCT ID:** NCT05683548
- **Lead sponsor:** Replicor Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05683548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05683548, "Replicor Compassionate Access Program". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05683548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*